Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China
August 05, 2021 at 02:00 am EDT
Share
Inmagene Biopharmaceuticals and Kissei Pharmaceutical Co., Ltd. announced that they have entered into an exclusive license agreement for the development and commercialization of fostamatinib in mainland China, Hong Kong and Macau. Under the terms of the agreement, Inmagene will obtain exclusive rights to develop and commercialize fostamatinib in all potential indications in China. In return, Kissei will receive an upfront payment and milestone payments based on the progress of development and commercialization.
KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.
KISSEI PHARMACEUTICAL CO., LTD. 
